MX379057B - Compuestos de benzoxaborol y uso de los mismos. - Google Patents

Compuestos de benzoxaborol y uso de los mismos.

Info

Publication number
MX379057B
MX379057B MX2017010413A MX2017010413A MX379057B MX 379057 B MX379057 B MX 379057B MX 2017010413 A MX2017010413 A MX 2017010413A MX 2017010413 A MX2017010413 A MX 2017010413A MX 379057 B MX379057 B MX 379057B
Authority
MX
Mexico
Prior art keywords
sub
sup
compounds
benzoxaborol compounds
benzoxaborol
Prior art date
Application number
MX2017010413A
Other languages
English (en)
Spanish (es)
Other versions
MX2017010413A (es
Inventor
M R K Alley ( Dickon)
Carlos Alemparte-Gallardo
David Barros-Aguirre
Ilaria Giordano
Jacob J Plattner
Vincent Hernandez
Xianfeng Li
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX379057(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2017010413A publication Critical patent/MX2017010413A/es
Publication of MX379057B publication Critical patent/MX379057B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2017010413A 2015-02-12 2016-02-12 Compuestos de benzoxaborol y uso de los mismos. MX379057B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15382055 2015-02-12
EP15382056 2015-02-12
EP15382054 2015-02-12
PCT/IB2016/050775 WO2016128948A1 (en) 2015-02-12 2016-02-12 4 -substituted benzoxaborole compounds and uses thereof

Publications (2)

Publication Number Publication Date
MX2017010413A MX2017010413A (es) 2018-05-11
MX379057B true MX379057B (es) 2025-03-10

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010413A MX379057B (es) 2015-02-12 2016-02-12 Compuestos de benzoxaborol y uso de los mismos.
MX2017010414A MX2017010414A (es) 2015-02-12 2016-02-12 Compuestos de benzoxaborol y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017010414A MX2017010414A (es) 2015-02-12 2016-02-12 Compuestos de benzoxaborol y usos de los mismos.

Country Status (36)

Country Link
US (3) US20180037595A1 (enExample)
EP (2) EP3256480A1 (enExample)
JP (2) JP2018506540A (enExample)
KR (2) KR20170117158A (enExample)
CN (2) CN107548398A (enExample)
AU (3) AU2016217508A1 (enExample)
BR (2) BR112017017211B1 (enExample)
CA (2) CA2976030C (enExample)
CL (2) CL2017002060A1 (enExample)
CO (2) CO2017008816A2 (enExample)
CR (2) CR20170371A (enExample)
CY (1) CY1123687T1 (enExample)
DK (1) DK3256479T3 (enExample)
DO (2) DOP2017000189A (enExample)
EA (2) EA036516B1 (enExample)
ES (1) ES2821951T3 (enExample)
HR (1) HRP20201597T1 (enExample)
HU (1) HUE051113T2 (enExample)
IL (2) IL253864B (enExample)
LT (1) LT3256479T (enExample)
MA (2) MA41495A (enExample)
MX (2) MX379057B (enExample)
MY (1) MY194004A (enExample)
NZ (1) NZ734379A (enExample)
PE (2) PE20171432A1 (enExample)
PH (2) PH12017501427A1 (enExample)
PL (1) PL3256479T3 (enExample)
PT (1) PT3256479T (enExample)
RS (1) RS60885B1 (enExample)
SG (2) SG11201706511TA (enExample)
SI (1) SI3256479T1 (enExample)
SM (1) SMT202000565T1 (enExample)
TW (2) TWI730953B (enExample)
UA (1) UA120527C2 (enExample)
WO (2) WO2016128949A1 (enExample)
ZA (1) ZA201705456B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
DK3621609T3 (da) 2017-05-08 2022-08-29 Glaxosmithkline Ip Dev Ltd Sanfetrinem eller et salt eller ester deraf til anvendelse i behandling af mykobakterieinfektion
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
EP3836938A4 (en) 2018-08-18 2022-05-11 Boragen, Inc. SOLID FORMS OF SUBSTITUTED BENZOXAZOLE AND COMPOSITIONS THEREOF
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
CA3239097A1 (en) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Prodrugs of boron compounds and their use in treating bacterial infections
JP2025520237A (ja) * 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ, インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
SG172040A1 (en) 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
AU2011237681B2 (en) * 2010-04-07 2015-01-22 Glaxosmithkline Llc Process for preparing benzoxaboroles
DK2613788T3 (en) 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US8530452B2 (en) 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof

Also Published As

Publication number Publication date
HRP20201597T1 (hr) 2020-12-25
CN107531730B (zh) 2020-08-07
EA201791667A1 (ru) 2018-02-28
HUE051113T2 (hu) 2021-01-28
US10774096B2 (en) 2020-09-15
NZ734379A (en) 2023-06-30
MY194004A (en) 2022-11-07
WO2016128948A1 (en) 2016-08-18
LT3256479T (lt) 2020-12-28
KR20170117156A (ko) 2017-10-20
SG11201706511TA (en) 2017-09-28
SMT202000565T1 (it) 2020-11-10
CY1123687T1 (el) 2022-03-24
TW201702250A (zh) 2017-01-16
CO2017008809A2 (es) 2017-11-10
PH12017501428A1 (en) 2018-01-15
CA2976308A1 (en) 2016-08-18
CO2017008816A2 (es) 2017-11-10
BR112017017211A2 (pt) 2018-04-03
JP2018506538A (ja) 2018-03-08
JP6771472B2 (ja) 2020-10-21
DOP2017000189A (es) 2018-02-15
MX2017010414A (es) 2018-05-11
IL253865A0 (en) 2017-10-31
KR20170117158A (ko) 2017-10-20
US11214582B2 (en) 2022-01-04
JP2018506540A (ja) 2018-03-08
TW201643173A (zh) 2016-12-16
PH12017501427A1 (en) 2018-01-15
US20180037595A1 (en) 2018-02-08
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
BR112017017211B1 (pt) 2023-04-25
MA41495A (fr) 2017-12-19
CA2976030C (en) 2023-09-26
PL3256479T3 (pl) 2021-06-14
EP3256480A1 (en) 2017-12-20
AU2016217508A1 (en) 2017-09-28
AU2020256369A1 (en) 2020-11-12
IL253864B (en) 2021-07-29
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
AU2016217507B2 (en) 2019-03-14
EA201791671A1 (ru) 2018-02-28
WO2016128949A1 (en) 2016-08-18
CA2976030A1 (en) 2016-08-18
EP3256479A1 (en) 2017-12-20
TWI730953B (zh) 2021-06-21
MA41494B1 (fr) 2020-10-28
DK3256479T3 (da) 2020-11-02
MA41494A (fr) 2017-12-19
EP3256479B1 (en) 2020-07-29
US20210053996A1 (en) 2021-02-25
ZA201705456B (en) 2019-10-30
SG11201706510YA (en) 2017-09-28
BR112017017213A2 (pt) 2018-04-03
CR20170371A (es) 2018-01-22
IL253864A0 (en) 2017-09-28
RS60885B1 (sr) 2020-11-30
PE20171348A1 (es) 2017-09-13
DOP2017000188A (es) 2017-09-15
US20180044353A1 (en) 2018-02-15
PE20171432A1 (es) 2017-09-26
AU2016217507A1 (en) 2017-09-28
CN107531730A (zh) 2018-01-02
CR20170372A (es) 2017-10-19
CN107548398A (zh) 2018-01-05
ES2821951T3 (es) 2021-04-28
EA036516B1 (ru) 2020-11-18
CL2017002060A1 (es) 2018-03-16
CL2017002059A1 (es) 2018-03-16

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
MX373935B (es) Compuestos antiproliferativos y métodos de uso de los mismos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
EA201691302A1 (ru) Новые гетероциклические соединения
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA201591781A1 (ru) Химические соединения
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2019007339A (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos.
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201991595A1 (ru) Активатор nrf2
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения